In Vitro and in Vivo Cytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma

Cancer Research

Volumn 64, Issue 4, 2004, Pages 1419-1424

  Onda, Masanori ^a   Wang, Qing Cheng ^a   Guo, Hong Fen ^b   Cheung, Nai Kong V ^b   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 8H9; PSEUDOMONAS EXOTOXIN; RECOMBINANT IMMUNOTOXIN 8H9(FV) PE38; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER THERAPY; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FUSION GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONKEY; MOUSE; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; SCID MOUSE; TUMOR REGRESSION;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL TOXINS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; EXOTOXINS; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; MACACA FASCICULARIS; MICE; MICE, SCID; NEUROBLASTOMA; OSTEOSARCOMA; RECOMBINANT FUSION PROTEINS; VIRULENCE FACTORS;

EID: 1242271212     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-0570     Document Type: Article

References (25)

1. Pastan, I. Targeted therapy of cancer with recombinant immunotoxin. Biochim. Biophys. Acta Rev. Cancer, 1333: C1-C6, 1997.
2. Kreitman, R. J., Bailon, P., Chaudhary, V. K., FitzGerald, D. J. P., and Pastan, I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood, 83: 426-434, 1994.
3. Pai, L. H., Batra, J. K., FitzGerald, D. J., Willingham, M. C., and Pastan, I. Antitumor activities of immunotoxins made of monoclonal-antibody B3 and various forms of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 88: 3358-3362, 1991.
4. Mansfield, E., Amlot, P., Pastan, I., and FitzGerald, D. J. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood, 90: 2020-2026, 1997.
5. Chowdhury, P. S., Viner, J. L., Beers, R., and Pastan, I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. USA, 95: 3358-3362, 1998.
6. Batra, J. K., Kasprzyk, P. G., Bird, R. E., Pastan, I., and King, C. R. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 89: 5867-5871, 1992.
7. Onda, M., Olafsen, T., Tsutsumi, Y., Bruland, O. S., and Pastan, I. Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A. J. Immunother., 24: 144-150, 2001.
8. Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S., Giardina, S., Waldman, T. A., and Pastan, I. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol., 18: 1622-1636, 2000,
9. Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., and Pastan, I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med., 345: 241-247, 2001.
10. Modak, S., Kramer, K., Gultekin, S. H., Guo, H. F., and Cheung, N. V. Monoclonal antibody 8H9 targets a novel surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res., 61: 4048-4054, 2001.
11. Reiter, Y., Brinkmann, U., Lee, B., and Pastan, I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat. Biotechnol., 14: 1239-1245, 1996.
12. Cheung, N. K. V., Guo, H. F., Modak, S., and Cheung, I. Y. Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins. Hybrid. Hybridomics, 21: 433-443, 2002.
13. Brinkmann, U., Pai, L. H., FitzGerald, D. J., Willingham, M., and Pastan. I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA, 88: 8616-8620, 1991.
14. Brinkmann, U., Reiter, Y., Jung, S. H., Lee, B. K., and Pastan, I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc. Natl. Acad. Sci. USA, 90: 7538-7542, 1993.
15. Reiter, Y., Brinkmann, U., Kreitman, R. J., Jung, S-H., Lee, B., and Pastan I. Stabilization of the Fv fragment in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry, 33: 5451-5459, 1994.
16. Onda, M., Nagata, S., Tsutsumi, Y., Vincent, J. J., Wang, Q., Kreitman, R. J., Lee, B., and Pastan, I. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res., 61: 5070-5077, 2001.
17. Onda, M., Kreitman, R. J., Vasmatzis, G., Lee, B., and Pastan, I. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J. Immunol., 163: 6072-6077, 1999.
18. Chowdhury, P. S., Vasmatzis, G., Lee, B., and Pastan, I. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. J. Mol. Biol., 281: 917-928, 1998.
19. Buchner, J., Pastan, I., and Brinkmann, J. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem., 205: 263-270, 1992.
20. Nagata, S., Onda, M., Numata, Y., Santora, K., Beers, R., Kreitman, R. J., and Pastan, I. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin. Cancer Res., 8: 2345-2355, 2002.
21. Pai-Scherf, L. H., Villa, J., Pearson, D., Watson, T., Liu, E., Willingham, M. C., and Pastan, I. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin. Cancer Res., 5: 2311-2315, 1999.
22. Pai, L. H., Willes, R., Setser, A., Willingham, M. C., and Pastan, I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat. Med., 2: 350-353, 1996.
23. Chowdhury, P. S., and Pastan, I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol., 17: 568-572, 1999.
24. Beers, R., Chowdhury, P., Bigner, D., and Pastan, I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin. Cancer Res., 6: 2835-2843, 2000.
25. Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J., and Pastan, I. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res., 8: 995-1002, 2002.